The content on this site is intended for healthcare professionals only
Is precision myeloma medicine more hype than reality?
Asia-Pacific approaches to myeloma trials
Denosumab vs zoledronic acid for bone disease in newly diagnosed multiple myeloma
Bone disease and management of myeloma complications
Monoclonal antibodies in multiple myeloma
Treatment options for newly diagnosed multiple myeloma and management of bone disease: Roundtable at IMW 2017
Promising myeloma agents in phase II trials
Ongoing transplant phase III trials for myeloma
Post autologous transplant therapies in high risk multiple myeloma: StaMINA trial update
Updates from ASPIRE and ENDEAVOR: Multicenter phase III studies of carfilzomib for relapsed/refractory multiple myeloma
Pomalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma
How should we treat smoldering multiple myeloma? Expert discussion from IMW 2017
